rpcardioRational Pharmacotherapy in CardiologyРациональная Фармакотерапия в Кардиологии1819-64462225-3653«SILICEA-POLIGRAF» LLC10.20996/1819-6446-2006-2-3-65-68rpcardio-1035Research ArticleCURRENT QUESTIONS OF CLINICAL PHARMACOLOGYАКТУАЛЬНЫЕ ВОПРОСЫ КЛИНИЧЕСКОЙ ФАРМАКОЛОГИИNEW EVIDENCES OF POSSIBILITY OF OMEGA-3 ACIDS USE FOR MYOCARDIAL INFARCTION SECONDARY PREVENTIONНОВЫЕ ДОКАЗАТЕЛЬСТВА ВОЗМОЖНОСТИ ПРИМЕНЕНИЯ ОМЕГА-3 КИСЛОТ С ЦЕЛЬЮ ВТОРИЧНОЙ ПРОФИЛАКТИКИ ИНФАРКТА МИОКАРДАМартыновА. И.MartinovA. I.

Кафедра госпитальной терапии №1 лечебного факультета

Chair of hospital therapy №1, Medical Faculty

ХоменкоВ. Л.ChomenkoV. L.

Кафедра госпитальной терапии №1 лечебного факультета 

Chair of hospital therapy №1, Medical Faculty

Московский государственный медико-стоматологический университетРоссияMoscow State University of Medicine and StomatologyRussian Federation200624012016236568Copyright © Martinov A.I., Chomenko V.L., 20162016Мартынов А.И., Хоменко В.Л.Martinov A.I., Chomenko V.L.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpcardio.online/jour/article/view/1035

The metabolism, classification, biomedical implication and clinical application of polyunsaturated fatty acids (PUFAs) were analyzed. It was proved that PUFAs class omega-3 have positive effects on cardiovascular system. First of all, this is an antiarrhythmogenic action, which is accompanied by the increase in variability of heart rhythm. Omega-3 PUFAs cause the reduction in platelet activity and vasoactive mediator release (serotonin, thromboxane A2), vasodilatation, the reduction in inflammatory mediators release and endothelium permeability, the rising of endothelium dependent dilatation of vessels, the depression of vascular response on angiotensine П and noradrenalin. Omega-3 PUFAs are responsible for the reduction in blood pressure, the increase in erythrocytes elasticity, the fall of fibrinogen concentration and normalization of plasma lipid profile. Omega-3 PUFAs in large dozes show antiatherosclerotic effect. Clinical data showing that Omega-3 PUFAs increase in life time due to reduction in sudden death incidence were provided. It is suggested to use Omega-3 PUFAs (OMAKOR) for secondary prevention of ischemic heart disease and treatment of hypertriglyceridemia.

Рассматривают вопросы метаболизма, классификации, биологической роли и клинического применения полиненасыщенных жирных кислот (ПНЖК). Показано, что ПНЖК класса омега-3 обладают комплексом положительных сердечно-сосудистых эффектов. Это, прежде всего, антиаритмогенное действие, сочетающееся с увеличением вариабельности сердечного ритма. Омега-3 ПНЖК вызывают снижение активности тромбоцитов, уменьшение выхода сосудосуживающих медиаторов (серотонина, тромбоксана А2), снижение сосудистого тонуса, уменьшение выброса воспалительных медиаторов, уменьшение проницаемости эндотелия, увеличение эндотелийзависимой дилатации сосудов, уменьшение сосудистых реакций на  ангиотензин II и норадреналин. Омега-3 ПНЖК ответственны за снижение АД, увеличение эластичности эритроцитов, уменьшение концентрации фибриногена и нормализацию липидного профиля плазмы. В больших дозах омега-3 ПНЖК оказывают антиатеросклеротический эффект. Представлены данные клинических исследований, показывающих, что омега-3 ПНЖК увеличивают продолжительность жизни, прежде всего за счет снижение случаев внезапной смерти. Предлагается использовать препараты омега-3-ПНЖК (ОМАКОР) для вторичной профилактики ишемической болезни сердца, лечения гипертриглицеридемии.

омега-3 полиненасыщенные жирные кислотыперекисное окисление липидоввнезапная смертьинфаркт миокардагипертриглицеридемияomega-3 polyunsaturated fatty acidslipid peroxidationsudden deathmyocardial infarctionhypertriglyceridemiaReferencesLampe F.C., Whincup P.H., Wannamethee S.G., et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur. Heart J. 2000; 21: 1052-1062Lampe F.C., Whincup P.H., Wannamethee S.G., et al. The natural history of prevalent ischaemic heart disease in middle-aged men. Eur. Heart J. 2000; 21: 1052-1062Marchioli R., Rupp H. Высокоочищенные омега-3-жирные кислоты как средство вторичной профилактики инфаркта миокарда. Москва 2006: 1-81Marchioli R., Rupp H. Высокоочищенные омега-3-жирные кислоты как средство вторичной профилактики инфаркта миокарда. Москва 2006: 1-81Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of csrdiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356(9237): 1213 – 1218Boaz M., Smetana S., Weinstein T., et al. Secondary prevention with antioxidants of csrdiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet 2000; 356(9237): 1213 – 1218Albert C.M., Hennekens C.H., O’Donnell C.J., et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28Albert C.M., Hennekens C.H., O’Donnell C.J., et al. Fish consumption and risk of sudden cardiac death. JAMA 1998; 279: 23-28Chin J.P., Dart A.M. How do fish oils affect vascular function? Clin. Exp. Pharmacol. Physiol. 1995; 22:71-81Chin J.P., Dart A.M. How do fish oils affect vascular function? Clin. Exp. Pharmacol. Physiol. 1995; 22:71-81Sellmayer A., Witzgall H., Lorenz R.L., Weber P.C. Effects of dietary fish oil on ventricular premature complexes. Am. J. Cardiol. 1995; 76: 974-977Sellmayer A., Witzgall H., Lorenz R.L., Weber P.C. Effects of dietary fish oil on ventricular premature complexes. Am. J. Cardiol. 1995; 76: 974-977Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2(8666): 757-761Burr M.L., Fehily A.M., Gilbert J.F., et al. Effects of changes in fat, fish and fibre intakes on death and myocardial reinfarction: diet and reinfarction trial (DART). Lancet 1989; 2(8666): 757-761Kris–Etherton P.M., Taylor D.S., Yu-Poth S., et al. Polyunsaturated fatty acids in the food chain in the United States. Am. J. Clin. Nutr. 2000; 71 (1 Suppl.): 179S-188SKris–Etherton P.M., Taylor D.S., Yu-Poth S., et al. Polyunsaturated fatty acids in the food chain in the United States. Am. J. Clin. Nutr. 2000; 71 (1 Suppl.): 179S-188SMarckmann P., Bladbjerg E.M., Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Artherioscler. Thromb. Vasc. Biol. 1997; 17: 3384-3391Marckmann P., Bladbjerg E.M., Jespersen J. Dietary fish oil (4 g daily) and cardiovascular risk markers in healthy men. Artherioscler. Thromb. Vasc. Biol. 1997; 17: 3384-3391Marchioli R., Barzi F ., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)- Prevenzione. Circulation 2002; 105: 1897-1903Marchioli R., Barzi F ., Bomba E., et al. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)- Prevenzione. Circulation 2002; 105: 1897-1903Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long- chain n-3 fatty acids and the risk of sudden death. N Engl J. Med. 2002; 346: 1113-1118Albert C.M., Campos H., Stampfer M.J., et al. Blood levels of long- chain n-3 fatty acids and the risk of sudden death. N Engl J. Med. 2002; 346: 1113-1118Christensen J.H., Korup E., Aaroe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am.J. Cardi- ol., 1997; 79: 1670-1673Christensen J.H., Korup E., Aaroe J., et al. Fish consumption, n-3 fatty acids in cell membranes, and heart rate variability in survivors of myocardial infarction with left ventricular dysfunction. Am.J. Cardi- ol., 1997; 79: 1670-1673Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk patients after myocardial infarction. N.Engl.J.Med. 1998; 339: 489-497Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk patients after myocardial infarction. N.Engl.J.Med. 1998; 339: 489-497Task Force on Sudden cardiac Death of the European Society of Cardiology. Eur. Heart J. 2001; 22: 1374-1450Task Force on Sudden cardiac Death of the European Society of Cardiology. Eur. Heart J. 2001; 22: 1374-1450Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004): 781 – 786Stephens N.G., Parsons A., Schofield P.M., et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996; 347(9004): 781 – 786Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-1367Siscovick D.S., Raghunathan T.E., King I., et al. Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest. JAMA 1995; 274: 1363-1367Antithrombotic. Trialist’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86Antithrombotic. Trialist’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86Jha P, Flather M., Lonn E., et al. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann. Intern. Med. 1995; 123: 860-872Jha P, Flather M., Lonn E., et al. The antioxidant vitamins and cardiovascular disease. A critical review of epidemiologic and clinical trial data. Ann. Intern. Med. 1995; 123: 860-872Mehta R.H., Eagle K.A. Secondary prevention in acute myocardial infarction. BMJ 1998; 316: 838-842Mehta R.H., Eagle K.A. Secondary prevention in acute myocardial infarction. BMJ 1998; 316: 838-842Stein P.K., Kleiger R.E. Insights from the study of heart rate variability. Annu. Rev. Med. 1999; 50: 249-261Stein P.K., Kleiger R.E. Insights from the study of heart rate variability. Annu. Rev. Med. 1999; 50: 249-261

The authors declare that there are no conflicts of interest present.